Karon opens a gate in a farm field with a loaf of bread in a bag slung over her shoulder.
Karon opens a gate in a farm field with a loaf of bread in a bag slung over her shoulder.
Karon opens a gate in a farm field with a loaf of bread in a bag slung over her shoulder.

Country life, Karon’s way


Baking, family, and creating community in her dream location. That’s living Karon’s way.

It’s a crisp fall day and Karon is walking to her brother’s house nearby with a loaf of fresh-baked sourdough bread. She’s been able to do this more often, she says, after starting treatment with VYVGART in 2023. “I was able to bake more and to cook more, and to share more meals… to help more when they needed help.”

She says that it’s been refreshing to be able to do these things. “Back when we first moved here, I was the one who needed help the most.”

Karon was diagnosed with anti-AChR antibody positive gMG in 2010. She had to make changes to adapt to life with gMG, like relying on others more.

Back then, she lived just 10 minutes outside a major city. But about 4 years later, Karon and her husband made a big change—they moved to a 20-acre property in a rural town with fewer than 800 residents. They wanted an escape from crowds and traffic. But the move was about so much more than that.

A peaceful paradise shared by family

“I remember, when we first came to this property, thinking about how peaceful it was,” Karon says. “I thought of all the memories we were going to share here, the holidays and family gatherings.”

Now, family is just a few acres away. Karon’s parents, brother, and sister-in-law all went in on the property and built homes there. They share the land with some four-legged residents, too. A neighbor’s cattle regularly graze on the property, and the family enjoys walking to see the new calves with their dogs, Kaya and Molly.

“Being able to walk to each other’s houses is great,” says Karon—especially for her nephew, who loves playing outside. And it means support is close by if Karon needs help.

Karon and a friend sit on a park bench with coffee in to-go cups. Karon and a friend sit on a park bench with coffee in to-go cups. Karon and a friend sit on a park bench with coffee in to-go cups.

Strength in numbers: Karon’s support group

When she was first diagnosed with gMG, the nearest support group was hours away. But that didn’t stop Karon and her husband from making the drive—and it was worth it. “I had no idea how much it would help,” Karon says. “I needed other people with gMG in my life who were walking the same path.”

After receiving an outpouring of support, Karon and her husband wanted to pay it forward to others. They soon started a new support group in their area. “It’s been one of the best things that we’ve done throughout this journey,” Karon says. “It helped both of us because he needed it, as well.”


“I needed other people with gMG in my life who were walking the same path.”


The group has since grown to almost 200 members, and meets every month. Karon says that, even on bad days, helping someone else can help her, too. “We’re like a family. It gives me a lot of joy.”

Karon’s VYVGART journey

Karon first learned about VYVGART when a neurologist came to speak to her support group. It inspired Karon to talk to her own neurologist, who agreed that VYVGART could be a good fit for her based on its potential benefits and risks.

As part of that discussion, Karon’s doctor explained to her that patients should not use VYVGART for intravenous (IV) infusion or VYVGART Hytrulo for subcutaneous injection if they are allergic to any of their ingredients. These medicines may increase infection risk and cause serious allergic, infusion- or injection-related reactions. Most common side effects include respiratory and urinary tract infections and headache, as well as injection site reactions with VYVGART Hytrulo.

So, in November 2023, Karon started on VYVGART for IV infusion in addition to the oral gMG treatment she was already taking. In June 2024, she and her neurologist decided to move from VYVGART for IV infusion to VYVGART Hytrulo for subcutaneous injection.

“That’s really been a good treatment for me,” she says. “It’s given me the ability to do more activities. It’s given me more arm strength, more hand strength, less muscle fatigue. VYVGART Hytrulo has given me the ability to cook bread every week for friends and family, and to share it with people that I love.”

See more of Karon’s story

Creating community, one loaf at a time

These days, Karon bakes a few loaves a week to share with family and friends. “It’s a way to show them how much I love them,” she says. “And to say thank you for helping me when I needed it.”

Being able to host the people she loves—and feed them—means a lot to Karon. She recently cooked a gourmet meal for her parents’ anniversary celebration, and hopes to do the same for the holidays.

Karon’s got a lot to look forward to. But first, she’s got a bread delivery to make.

Karon is a paid spokesperson taking VYVGART Hytrulo.

Read more from MY Way Magazine

VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab)
VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) | VYVGART (efgartigimod alfa-fcab)

Still have questions? Call 1-833-VYVGART (1-833-898-4278) to speak with an educator about gMG, how VYVGART works in the body, study data, cost and coverage, and more.

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:

    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • trouble breathing
    • low blood pressure
    • fainting

    An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

  • Infusion or injection-related reactions. VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG).

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.

Do not take VYVGART if you are allergic to efgartigimod alfa or any of the ingredients in VYVGART. Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART or VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART or VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART or VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART or VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART or VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART or VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART or VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART or VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART or VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction with VYVGART or VYVGART HYTRULO:

    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • trouble breathing
    • low blood pressure
    • fainting

    An additional symptom of an allergic reaction with VYVGART HYTRULO can include hives.

  • Infusion or injection-related reactions. VYVGART can cause infusion-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART infusion or VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART or VYVGART HYTRULO include respiratory tract infection, headache, and urinary tract infection. An additional common side effect with VYVGART HYTRULO includes injection site reactions.

These are not all the possible side effects of VYVGART or VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART® (efgartigimod alfa-fcab) for intravenous (IV) infusion and what is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection?

VYVGART and VYVGART HYTRULO are both prescription medicines used to treat adults with generalized myasthenia gravis (gMG).

It is not known if VYVGART or VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO for subcutaneous injection and full Prescribing Information for VYVGART for IV infusion.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial. VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.